AZD 3759

Drug Profile

AZD 3759

Alternative Names: AZD-3759; EGFR antagonist - AstraZeneca; Epidermal growth factor receptor tyrosine kinase inhibitor - AstraZeneca

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator AstraZeneca
  • Class Amines; Antineoplastics; Piperazines; Quinazolines
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer

Most Recent Events

  • 29 Apr 2016 Biomarkers information updated
  • 31 Dec 2015 Phase-II clinical trials in Non-small cell lung cancer in United Kingdom (PO) (AstraZeneca's pipeline, February 2016)
  • 01 Nov 2014 Phase-I clinical trials in Non-small cell lung cancer (Second-line therapy or greater, Late-stage disease) in South Korea (PO) (NCT02228369)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top